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Abstract
Background: We have previously demonstrated that a mixture of Curcuminoids extract, hydrolyzed COllagen and
green Tea extract (CCOT) inhibited inflammatory and catabolic mediator’s synthesis by bovine and human
chondrocytes. A randomly allocated, double-blind, prospective, placebo-controlled study was performed to evaluate
the efficacy of a diet containing this CCOT mixture on dogs with naturally occurring osteoarthritis (OA). Therefore,
42 owner’s dogs with OA were randomly assigned to receive for 3 months an experimental diet (control) or the
same diet supplemented with CCOT.
Results: Ground reaction forces did not show statistical differences between groups. After 3 months of feeding,
there was a significant reduction of pain at manipulation in the CCOT group, but not in the control group. The
evolution for pain at manipulation depended on the diet. The three other parameters evaluated by veterinary
subjective assessment (lameness, pain at palpation and joint mobility) did not show statistical differences.
Concerning owner subjective assessment, pain severity score worsened in the control group but remained stable in
CCOT group. The evolution for pain severity depended on the diet. No statistical difference was found for pain
interference, except for the ability to rise to standing from lying down, which was significantly improved in the
CCOT compared to the control group. Serum OA biomarkers did not show statistical differences.
Conclusions: Objective variables measured, such as ground reaction forces and OA biomarkers, did not show
statistical differences. However, indicators of pain appeared reduced in dogs receiving CCOT mixture for 3 months.
The difference of evolution between groups suggests that a greater number of dogs may be necessary to reach a
stronger effect on other parameters.
Keywords: Osteoarthritis, Dog, Diet, Curcumin, Hydrolyzed collagen, Green tea polyphenols
* Correspondence: yhenrotin@ulg.ac.be
1Bone and Cartilage Research Unit, Arthropôle Liège, University of Liège,
Liège, Belgium
5Physical Therapy & Rehabilitation Department, Princess Paola Hospital,
Vivalia, Marche-en-Famenne, Belgium
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Comblain et al. BMC Veterinary Research  (2017) 13:395 
DOI 10.1186/s12917-017-1317-8
Background
Osteoarthritis (OA) is a chronic, painful, degenerative and
inflammatory condition that affects the synovial joints. It
is highly prevalent in dogs [1, 2] with 20% of the canine
population over one year old affected [3, 4]. This musculo-
skeletal disease is related to chronic pain, lameness, loss of
joint function and mobility, functional disability and
reduced quality of life [5]. The management of OA in dogs
is a lifetime commitment, involving a multimodal
approach. The main recommendation is to control symp-
toms by reducing pain, improving mobility and hence
quality of life; whilst protecting joints from OA [6].
To decrease pain and inflammation associated with
OA, non-steroidal anti-inflammatory drugs (NSAIDs)
are commonly prescribed [5]. Indeed, in clinical practice,
many dogs suffering from OA are long term treated with
NSAIDs such as carprofen [6]. NSAIDs act mostly by
inhibiting cyclo-oxygenase and thus reducing the con-
centration of pro-inflammatory prostaglandins. Unfortu-
nately, the use of NSAIDs may be associated with
adverse effects, especially gastrointestinal tract ulcera-
tions [7, 8]. Corticosteroid injection in dogs is usually re-
served for severe end stage OA and for cases that have
become refractory to other treatments [5]. Beside pain
relief, preventing cartilage degradation is an important
objective for treatment. This requires the long term use
of safe therapies, while the absence of any cure rein-
forces the importance of prevention [9]. Such prevention
and alternative solutions could come from nutrition or
from dietary supplements. Indeed, these latter present
the advantage of having few or no known side effects.
In a preliminary in vitro study [10], we have demon-
strated that a mixture of curcuminoids extract, hydro-
lyzed collagen and green tea extract (CCOT) inhibited
inflammatory and catabolic mediator’s synthesis by
bovine and human chondrocytes. These findings suggest
a scientific rationale for the evaluation of these natural
ingredients in a clinical trial. Curcumin is the major
component of turmeric, a yellow spice derived from the
rhizomes of the plant Curcuma longa. Evidence has been
published for its potency to target multiple inflammatory
diseases [11]. The main characteristic of hydrolyzed col-
lagen is its amino acid composition, which is identical to
collagen, thus providing high levels of glycine and pro-
line, two amino acids essential for the stability and re-
generation of cartilage [12, 13]. Green tea contains
polyphenolic fractions called catechins and, among
them, epigallocatechin-3-gallate, which exhibits anti-
oxidant, anti-tumoral and anti-mutagenic activities [14].
This randomly allocated, double-blind, prospective,
placebo-controlled clinical trial aimed to evaluate the ef-
fects of a diet containing CCOT mixture on client
owned dogs with OA using objective variables such as
force plate analysis and serum OA biomarkers (Coll2–1
and Coll2–1 NO2) as well as subjective variables such as
orthopedic evaluation and owner assessment [15].
Methods
Dogs
Dogs with OA were recruited among the patients of the
Veterinary Hospital of the University of Liege, or
through advertisements in pet stores, veterinarians’, dog
magazines, daily papers, websites with animal news,
grooming salons and pet associations. The (potential)
participants were informed about the purpose and
design of the trial.
Inclusion criteria were the presence of clinical (such as
lameness) and radiographic (such as the presence of
osteophytes, subchondral bone sclerosis) signs of OA on
at least one limb, to be older than 18 months and weigh
over 10 kg with a body condition score lower than 8 (on
a 9-point scale) [16], without evidence of systemic
disease identified by history and results of physical
examination, serum biochemical analysis and urinalysis.
Non-inclusion criteria were as follows: signs of lumbo-
sacral disease or neurologic deficit, acute traumatic in-
juries (including OA acute crises), treatment with
NSAIDs, corticosteroids or antimicrobials within 14 days
before enrolment, surgery on any joint within 6 months
before enrolment, aggressive behavior, and pregnancy or
likelihood of becoming pregnant during the study. For
ethical reasons, analgesics (tramadol, 2–5 mg/kg, 2–3
times a day) were allowed, except within 48 h before the
evaluation.
Dogs were excluded from the study for the following
reasons: development of an adverse reaction, injury or
illness that required treatment or surgical intervention,
excessive pain or other complications as determined by
the investigator, lack of owner compliance with study re-
strictions, and death of the dog because of natural
causes or owner-elected euthanasia.
Study diets
The 2 study diets were an experimental diet (control) or
the same diet supplemented with CCOT mixture
(CCOT) (Table 1). Both dry dog food products had simi-
lar nutritional and energy content (3515 kcal/kg) and
similar visual aspect. Energy requirements for dogs were
based on the equation published by the National Re-
search Council in 2006: 95 kcal/kg0.75 body weight [17,
18]. Both diets were supplied by the manufacturer in
identical neutral bags but differentiated by their code
names. The diet with the CCOT mixture contained
0.43 g curcuma extract per 1000 kcal, 4.27 g hydrolyzed
collagen per 1000 kcal and 0.85 g green tea extract per
1000 kcal. Curcuma extract (Indena, Paris, France)
contained between 18 and 22% of curcuminoids and was
associated with a phosphatidylcholine complex to
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increase its bioavailability [19]. Peptides constituting
hydrolyzed collagen (Gelita, Eberbach, Germany) were
composed of 30 amino acids peptides. Glycine and proline
represented more than 35% of total amino acids content.
Green tea extract (Naturex, Avignon, France) contained
25% polyphenols, which represented 12.5% catechins
representing more than 9.3% epigallocatechin-3-gallate.
Study protocol
The study was designed as a 3-month double-blind, ran-
domly allocated, prospective, placebo-controlled clinical
trial, adhering to the CONSORT guidelines [20]. All
owners received a detailed written description of the
protocol and provided written informed consent before
the inclusion of their dog in the study. The protocol was
approved by the Institutional Animal Care and Use Eth-
ics Committee of the University of Liège (reference 12–
1330) and by the Royal Canine Ethics Committee. They
adhere to a high standard of veterinary care. Investiga-
tors collected blood samples at the first screening visit
for serum biochemistry which validated dog eligibility
for the study. Eligible dogs were randomly assigned
(using Microsoft Office Excel 2013) to receive either the
control diet or the CCOT supplemented diet. A statisti-
cian generated the random allocation sequence. Block
size was 10. Allocation ratio was 1:1. The allocation
sequence was not concealed but neither pet owners,
neither veterinarians nor investigators had knowledge of
the diet to which dogs were assigned. A veterinarian en-
rolled dogs. Upon enrollment in the study, pet owners
were instructed to feed their dogs on a transition diet
(same composition as control but kibble of a different
shape) over 14 days. In this way, all eligible dogs
received the same diet (without any potential active
compound included within the diet) before starting the
study. Feeding guidelines were provided to owners with
the intent for dogs to maintain a constant body weight
and condition as well as to be fed according to their
usual feeding regimen (free choice or meal). An investi-
gator assigned dogs to interventions. Dogs were weighed
each month.
Adverse events
During the study, all adverse events were reported to the
investigator, who noted the event characteristics includ-
ing severity, occurrence and suspected association with
the food.
Objective measurement: force plate analysis
Ground reaction forces were measured with kinetic ana-
lysis using biomechanical force platforms (Kistler, Win-
terthur, Switzerland) at the Laboratory of Human
Motion Analysis at the University of Liège. At study
start (T0 = inclusion +14 days of transition diet), the
limb most affected by lameness, as shown by peak verti-
cal force (PVF) gait analysis and orthopedic examination,
and with radiographic OA lesions was defined as “the
most affected limb” and followed throughout the study.
Dogs were acclimated to the force plate before data col-
lection. Data for the right and left sides were collected
from separate passes across the plate. The limb most af-
fected by lameness, as shown by PVF gait analysis and
orthopedic examination, and with radiographic OA le-
sions was considered as the most affected limb and its
contralateral limb was considered as less affected limb
(compared to its contralateral most affected limb).
Ground reaction forces were recorded at T0 and after
3 months of diet (T3). The owner trotted dogs across
the force plate, and an investigator observed and filmed
each pass to confirm foot strikes and gait. A test was
considered valid when only one limb landed on the force
plate at a time, while the dog was trotted across it at a
velocity of 1.8 to 2.2 m/s and acceleration-deceleration
variation of ±0.5 m/s2. The dog’s forward velocity was
measured with a 3D sensor (Charnwood Dynamics,
Rothley, United Kingdom) placed on the back of the
dog. Five valid tests were obtained for each limb.
PVF, braking and propulsive peak forces, vertical im-
pulse, braking and propulsive impulses, and loading and
unloading rates were measured and analyzed using the
software CODAmotion (V6.78.1) (Charnwood Dynam-
ics). All parameters were normalized by body weight
(BW) (Newton) and expressed in % of BW. Data from
five valid tests of each most affected and less affected
limb were averaged as previously described [21]. PVF
has been defined as the primary outcome of our study.
Based on this outcome, we determined the positive and
negative responder’s rates for control and COT groups
[22]. We used the minimal detectable change, at the 95%
Table 1 Composition of both study diets
Unit Control CCOT
Moisture % 12,2 12,1
Protein % 20,5 20,5
Fat % 11,7 11,7
Ash % 6,0 5,9
Crude fiber % 4,0 4,0
Total dietary fiber % 9,0 9,0
Nitrogen free extract % 40,2 39,9
Glycine % 0,7 1,0
Hydroxyproline % 0,002 0,2
Proline % 1,1 1,2
Curcuminoids extract % 0 0,15
Hydrolyzed collagen % 0 1,5
Green tea polyphenols % 0 0,3
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level (MDC95), which reflected a real change. A change
of at least 3.6% BW in PVF measurement, when
expressed relatively to baseline values, at the 95% level,
needed to occur to be confident [22].
Subjective measurement: orthopedic evaluation
At inclusion visit and T3, dogs were examined by a vet-
erinarian specialized in orthopedic surgery. Two ortho-
pedists participated in the study. One orthopedist
evaluated 24 dogs, and another 18 dogs. The same veter-
inarian performed a dog’s assessment at T0 and at T3.
Lameness (1 to 5), pain at manipulation (0 to 10), pain
at palpation (1 to 5) and joint mobility (1 to 5) were
evaluated as previously described [23, 24]. The scoring
system is described in Table 2. Pain at manipulation was
evaluated on a scale from 0 to 10, 0 corresponding to no
pain, and 10 corresponding to extreme pain [24]. Pain
upon limb manipulation was evaluated by animals’
vocalization or other observations of pain during the
extension and flexion of all four limbs for a period of
several minutes.
Subjective measurement: owner assessment
Owners evaluated their dog’s condition at T0 and T3 by
completing a validated Canine Brief Pain Inventory
(CBPI), a questionnaire assessing pain severity (PS) and
pain interference (PI) [15]. The questionnaire was trans-
lated in French. The same owner evaluated his/her dog
at T0 and T3. The 4 PS questions (worst pain in the last
7 days, least pain in the last 7 days, average pain in the
last 7 days and pain right now) were scored on a nu-
meric scale from 0 (no pain) to 10 (extreme pain). The
scores of each question were averaged to generate the
global PS score. Each criterion was considered with
the same weighing. The 6 PI questions (i.e., how
much the pain interfered with the dog’s typical func-
tion: general activity, enjoyment of life, ability to rise
to standing from lying down, ability to walk, ability
to run and ability to climb up) were scored on a
numeric scale from 0 (does not interfere) to 10 (com-
pletely interferes). The scores of each question were
averaged to generate the global PI score. Each criter-
ion was considered with the same weighing.
Objective measurement: OA biomarkers
Blood samples were collected each month (T0, after
1 month of diet (T1), after 2 months of diet (T2) and
T3) and OA biomarkers (Coll2–1 and Coll2–1 NO2)
were quantified by competitive immunoassays (Artialis
SA, Liège, Belgium). All Coll2–1 and Coll2–1NO2 tests
have been performed by Artialis in collaboration with
Bone and Cartilage Research Unit.
These assays are competitive immunoassays utilizing a
synthetic peptide pre-coated onto the ELISA plate for
the quantification of the corresponding antigen in sam-
ples. A binding competition between the immobilized
peptide and the peptide contained in the standards or
samples takes place upon addition of the antibodies.
After removal of the unbound peptide, a peroxidase-
conjugated goat anti-rabbit antibody is added into each
well to detect and quantify the level of competitive bind-
ing. After washing of the unbound detection antibody,
the antibody-antigen complex is detected by a chromo-
genic reaction with 3, 3′, 5, 5′-tetramethylbenzidine
(TMB). The reaction is stopped by adding acid to give a
colorimetric endpoint that is subsequently determined
spectrophotometrically.
Coll2–1 was quantified in dog sera by competitive
ELISA in triplicate with polyclonal rabbit antisera (ab-
Coll2–1; Artialis) using buffers specifically developed to
measure these fragments in dog serum (confidential
composition). A 6-fold dilution of samples has been ap-
plied. Intraassay coefficient of variation (CV) was 3.6%
and interassay CV was 9.8%.
Coll2–1-NO2 was quantified in dog sera by competi-
tive ELISA according to the methodology cited above, in
triplicate, with polyclonal rabbit antisera (D37; Artialis)
using buffers specifically developed to measure these
fragments in dog serum (confidential composition). A 2-
fold dilution of samples has been applied. Intraassay CV
was 5.8% and interassay CV was 4.7%.
Table 2 Clinical scoring system for assessing dogs with
osteoarthritis
Criterion Grade Clinical evaluation
Lameness 1 Walk normally
2 Slightly lame when walking
3 Moderately lame when walking
4 Severely lame when walking
5 Reluctant to rise and will not walk
more than five paces
Pain at palpation 1 None
2 Mild signs; dog turns head in recognition
3 Moderate signs; dog pulls limb away
4 Severe signs; dog vocalizes or becomes
aggressive
5 Dog will not allow palpation
Joint mobility 1 Full range of motion
2 Mild limitation (10 ∼ 20%) in range
of motion; no crepitus
3 Mild limitation (10 ∼ 20%) in range of motion;
crepitus
4 Moderate limitation (20 ∼ 50%) in range of
motion; ± crepitus
5 Severe limitation (>50%) in range of
motion; ± crepitus
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Statistical analysis
The number of dogs needed, on a statistical point of
view, was calculated from a previous study evaluating
the effect of an extract of turmeric in OA dogs on PVF
[9]. Using the related effect size, this study was powered
at 80% with an alpha risk at 5%. A two-tailed test was
performed. Including a 10–20% margin for fallout
during the study, the optimal initial number of dogs was
determined between 46 and 50.
There was no change to trial outcomes after the trial
commenced. PVF was calculated in terms of PVF evolu-
tion as Δ T3-T0. PVF was assessed with a mixed model
including diet, limb effect (most/less affected), and inter-
action between diet and limb effect as fixed effects. As
given that BW influenced PVF, BW was entered as
covariate in PVF statistical analysis. Lameness, pain at
manipulation, pain at palpation and joint mobility were
also assessed using a mixed model including time, diet,
and the related interaction between time and diet as the
main effects. Dog was defined as a random term in
mixed models. PS and PI were assessed using general-
ized linear model. Diet, defined as the main effect, was
investigated on Δ T3-T0. Generalized linear model or
mixed model were analyzed using SAS 9.3. According to
data features and residuals distribution of each model,
the outcomes were previously rank transformed or not.
Homoscedasticity was checked on residuals with a white
test at a level of 1%. All data were expressed as mean ±
standard deviation. The analysis was two-sided. A p-
value ≤0.05 was considered as statistically significant.
Results
Dogs
One hundred and fifty five dog owners responded to the
advertising. After a phone interview to get additional in-
formation, 115 owners were invited with their dog to the
first screening visit. Of those 115 screened dogs, 48 were
found eligible for the study and were randomly assigned
to receive CCOT (n = 23) or control (n = 25) diet for
3 months. Two dogs in the CCOT and 4 in the control
groups were excluded from the study for the following
reasons: development of an illness that required treat-
ment (such as NSAIDs) or surgical intervention (3 con-
trol dogs), appearance of neurologic deficit (1 CCOT
dog), lack of owner compliance with study restrictions (1
control dog), and death of the dog because of owner-
elected euthanasia due to deterioration of general condi-
tion of the dog (1 CCOT dog). Consequently, 42 dogs
completed the study, including 21 from the CCOT group
and 21 from the control group (Fig. 1). Only dogs that
completed the study were included in the analysis (per-
protocol population). Two dogs in the control group
needed rescue analgesia during the study: one for 8 days
and one for 7 days. The periods of recruitment and
follow-up lasted for more than two years (from February
2013 to April 2015). The trial ended because between 46
and 50 dogs were enrolled in the study.
There were no significant differences concerning
population characteristics between control and CCOT
groups at T0 and T3 (Table 3). In the control group, the
following breeds were represented: mixed breed (n = 6),
Fig. 1 Flow diagram through study
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German Shepherd Dogs (n = 5), Bernese Mountain Dogs
(n = 2), Border Collies (n = 2), and 1 each of Australian
Shepherd, Bordeaux Mastiff, Braque d’Auvergne, Ger-
man Shorthaired Pointer, Golden Retriever, Rottweiler.
In the CCOT group, the following breeds were repre-
sented: Golden Retrievers (n = 5), Border Collies (n = 2),
Cockers (n = 2), German Shepherd Dogs (n = 2), Labra-
dors (n = 2), Newfoundland (n = 2) and 1 each of Aire-
dale Terrier, Bernese Mountain Dog, German Mastiff,
mixed breed, Pitbull-type dog, Saint-Bernard.
Tolerance
The CCOT diet was well tolerated. There was no signifi-
cant change in dogs’ body weight nor evidence of side
effects over the duration of the study. Three dogs in
CCOT group and 2 dogs in control group had mild diar-
rhea but it was minor and transient.
Objective measurement: force plate analysis
We recruited only few dogs affected by front and hind
limbs OA, and those dogs were « clinically » lame only
on one leg (usually the front limb). We did not recruit
any dogs with lameness on both front and hind limbs.
PVF values for the most severely affected limb were
not significantly different between control and CCOT
groups at T0 (p = 0.618) and T3 (p = 0.953). There was
no significant PVF change with time in control group
(T0: 69.65 ± 4.33% BW; T3: 69.63 ± 3.18% BW; p = 0.999)
and in CCOT group (T0: 61.81 ± 2.52% BW; T3: 67.44 ±
3.32% BW; p = 0.283). The PVF change (Δ T3-T0) was
not different between groups (p = 0.319) (Fig. 2).
Different levels of change in PVF measurement were
observed in dogs. The positive responder’s rate was
greater in CCOT group (47.6%) than in control group
(42.9%). Moreover, the negative responder’s rate was
greater in control group (23.8%) than in CCOT group
(14.3%). Indeed, among the 21 dogs in CCOT group, 13
(61.9%) had clinically meaningful changes, which were
positive in 10 (47.6%) or negative in 3 (14.3%) dogs.
Among the 21 dogs in control group, 14 (66.7%) had
clinically meaningful changes, which were positive in 9
(42.9%) or negative in 5 (23.8%) dogs (Fig. 3).
There were no significant differences between groups
for the vertical impulse, the braking and propulsive peak
forces, the braking and propulsive impulses and the
loading and unloading rates changes between T0 and T3
(data not shown).
Table 3 Characteristics of dogs which completed the study
Characteristics Control CCOT p-value
Total number of subjects 21 21 NA
Male/female 8/13 10/11 NA
Castrated male/sterilized female/intact 2/9/10 6/7/8 NA
Age at T0 (years) 7.50 ± 2.85 7.56 ± 3.07 0.952
Body weight at T0 (kg) 34.91 ± 11.66 36.43 ± 12.63 0.563
Body weight at T3 (kg) 35.17 ± 11.60 36.13 ± 12.95 0.717
Peak vertical force at T0 (% BW) 69.65 ± 19.86 61.81 ± 11.56 0.618
Pain at manipulation at T0 3.65 ± 2.50 4.19 ± 2.40 0.988
Pain severity at T0 2.46 ± 2.08 2.67 ± 1.82 0.680
Pain interference at T0 3.44 ± 2.71 3.26 ± 2.47 0.898
Most affected joint at T0
Carpus 1 0 NA
Elbow 5 2 NA
Stifle 2 6 NA
Hip 13 13 NA
Data were expressed as distributions (number of dogs) for categorical characteristics and as mean ± SD for continuous characteristics
T0 study start, T3 after 3 months of diet, study end, NA not applicable, BW body weight
Fig. 2 Mean ± SD for Δ PVF in OA dogs (n = 21 control +21 CCOT).
PVF = peak vertical force
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Subjective measurement: veterinary evaluation
Pain at manipulation was significantly decreased in the
CCOT group (T0: 4.19 ± 0.52; T3: 2.86 ± 0.51; p= 0.037) but
not in the control group (T0: 3.65 ± 0.56; T3: 3.7 ± 0.4, p=
0.999). Furthermore, the evolution for pain at manipulation
depended on the diet (p= 0.036) (Fig. 4). There was no sig-
nificant difference between groups for lameness, pain at pal-
pation and joint mobility at T0 and T3 (Table 4).
Subjective measurement: owner assessment
Regarding owner’s assessment, PS did not change in the
control (T0: 2.46 ± 0.45; T3: 3.58 ± 0.51; p = 0.071) or the
CCOT group (T0: 2.67 ± 0.4; T3: 2.42 ± 0.38: p = 0.35).
The PS change (ΔT3-T0) was significantly different be-
tween CCOT and control groups (p = 0.009) (Fig. 5a).
There was no significant difference for PI change be-
tween CCOT (T0: 3.26 ± 0.54; T3: 2.96 ± 0.45; p = 0.101)
and control groups (T0: 3.44 ± 0.59; T3: 3.86 ± 0.66; p =
0.633) (p = 0.063) (Fig. 5b). However, when each ques-
tion of the PI score was analyzed separately, PI change
(Δ T3-T0) on the ability to rise to standing from lying
down was significantly improved in CCOT group com-
pared to control group (p = 0.029).
Objective measurement: OA biomarkers
Coll2–1 and Coll2–1 NO2 serum concentrations were
not significantly different between control and CCOT
groups at T0 and T3. No significant changes over time
in Coll2–1 and Coll2–1 NO2 serum concentrations were
observed in both groups.
Discussion
The results of this study suggest that there is some bene-
fit in feeding symptomatic OA dogs with a diet contain-
ing the CCOT mixture, even if the primary outcome
(PVF, objective variable) was not improved.
Interestingly, our study showed that the veterinary
subjective assessment pain at manipulation was de-
creased by more than 30% by CCOT diet. These data
are consistent with that of a study evaluating the effects
of curcuma extract in owner’s dogs [9]. Another study
Fig. 3 Individual changes in PVF measured at T3 in OA dogs.
Changes were the difference between T3 and T0. Dashed lines
represent the minimal detectable change, when expressed relatively
to baseline values, at the 95% level. T0 = study start; T3 = study end
Fig. 4 Mean ± SD for pain at manipulation at T0 and T3 in OA dogs
(n = 21 control +21 CCOT). T0 = study start; T3 = study end; *p < 0.05
Table 4 Mean ± SD for lameness, pain at palpation and joint
mobility of the most severely affected limb in OA dogs
T0 T3 Time*diet p-value
Lameness
Control (n = 21) 1.8 ± 0.77 1.95 ± 1.05 0.244
CCOT (n = 21) 2.19 ± 0.87 1.86 ± 0.96
Pain at palpation
Control (n = 21) 2.45 ± 0.94 2.55 ± 0.94 0.195
CCOT (n = 21) 2.62 ± 0.92 2.1 ± 0.94
Joint mobility
Control (n = 21) 2.3 ± 1.08 2.75 ± 1.25 0.815
CCOT (n = 21) 2.71 ± 1.42 2.7 ± 1.22
T0 study start, T3 after 3 months of diet
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evaluating the effect of undenatured type II collagen also
demonstrated a decrease in pain upon limb manipula-
tion [25]. Pain improvement was not associated with
lameness improvement. Indeed, constraints and move-
ment amplitudes are different. This may also be ex-
plained by the fact that manipulation investigates pain
coming from the peri-articular tissue while lameness
could be partially generated by pain triggered by sub-
chondral bone loading.
Assessments by owners are subjective measures but,
when such measures are used, a composite score is more
effective than individual scores [26]. In the present
study, we used the validated CBPI which includes two
composite scores: PS and PI [15]. Regarding owner’s as-
sessment, the evolution for PS, as assessed by ΔT3-T0,
was significantly different between CCOT and control
groups, with the CCOT group staying stable and the
control group worsening. In contrast, no significant dif-
ference was observed for PI between CCOT and control
groups. This suggests that CCOT could affect pain but
not limb function. Nevertheless, when questions corre-
sponding to PI were analyzed separately, we found that
change (ΔT3-T0) in the ability to rise to standing from
lying down was significantly improved in the CCOT
compared to the control group. This is consistent with a
study showing that fish oil induced a significant im-
provement on the ability to rise from a resting position,
to play and to walk in OA dogs [27]. It has been shown
that the CBPI was not correlated with changes in force
plate data [21]. Pain mechanism during the weight bear-
ing is different. Moreover, owners considered that show-
ing improvements in quality of life (performing activities
of daily living) is much more important than demon-
strating enhancements in force plate data and increased
or decreased use of a single limb at a walk or trot [21].
Gait analysis has the limitation of only evaluating an ani-
mal at one specific time point, outside of its normal en-
vironment. On the contrary, CBPI quantifies the owners’
assessment of clinically relevant chronic pain–related
behaviors with the dog in its routine environment over
an extended period of time as well as how their dog is
doing “right now” [21].
However, PVF is often recognized as the most appro-
priate measure for assessing the effects of therapeutic
modalities in OA dogs and is frequently used in clinical
trials [26, 28, 29]. PVF was increased by a diet supple-
mented with fish oil omega-3 fatty acids [26, 30], with
type II collagen [24] and with green lipped mussel [31]
but not by an extract of curcuma [9]. PVF presents some
weaknesses, however. It is less reliable when used in
owner’s dogs. The fact that data for the most and less af-
fected limbs were mostly collected from separate runs
could also bring a bias. Minimal body weight of included
dogs was 10 kg. It may have been better to start with
higher body weight of dogs (e.g. 20 kg). Historically the
weight limitation was related to the ability for the force
plate to record a single stride (the size of the plate was
too big to have only one leg striking the plate at the
same time). Indeed, a small dog will have a faster joint
angular velocity than a big dog. That is why we com-
pared the difference between T0 and T3 on the same
dog, at the same velocity. We were based on a study in
which minimal body weight was 11.4 kg [26]. Addition-
ally, the gait analysis data combined thoracic and pelvic
limbs. This was problematic because PVF for the front
limb is higher than PVF for the hind limb. There was a
higher number of front limb OA dogs in control group
(n = 6) than in COT group (n = 2). Therefore PVF was
calculated as Δ T3-T0 but this heterogeneity may add a
bias to our study.
Moreover, PVF decrease has been demonstrated to be
more important in dogs affected by stifle OA than by
hip OA [32]. So we can speculate that the low ratio of
stifle OA in our population explains in part the absence
of effects of CCOT on PVF. Indeed in our study, 19% of
dogs had stifle OA while 62% had hip OA. Our popula-
tion was heterogeneous in terms of OA location. Some
dogs also had indirect signs of OA (such as a decreased
Fig. 5 Mean ± SD for Δ PS (a) and Δ PI (b) in OA dogs (n = 21 control
+21 CCOT). PS = pain severity; PI = pain interference; **p < 0.01
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range of motion or discrete discomfort on manipulation)
in multiple limbs. An improvement in one limb could hid-
den pain in others limbs. This is a limitation of this study.
However heterogeneous groups of dogs mimics the real
clinical situation in veterinary medicine. One could con-
sider this heterogeneity as a strength of our study.
The owner was the leash-driver for kinetics gait ana-
lysis. This is good for lowering stress associated with the
manipulation for the dog. But this could be another
source of inter-individuals variability, which may be con-
trolled by the same manipulator for each dog. Before the
beginning of the study, we compared kinetic analysis
when dogs were guided by their owners or by the ma-
nipulator. We concluded that dogs were less troubled
when they were guided by their owners. It was the same
owner who guided his/her dog at T0 and at T3. Indeed,
the dog response to a foreign manipulator is another
inter-individual variability. Anyway, all the trials were re-
corded at the same velocity, acceleration (with the dog
not turning its head). Dogs were also guided by their
owners in other similar studies [30, 33].
Because mean changes often obscure the individual
change, we presented individual changes in PVF for both
control and CCOT groups. We also calculated positive
and negative responder’s rates. The positive responder’s
rate was greater in CCOT group (47.6%) than in control
group (42.9%) whereas the negative responder’s rate was
greater in control group (23.8%) than in CCOT group
(14.3%). Reporting the percentages of dogs which met
the MDC95 requirements provided additional insightful
interpretations other than considering only the overall
mean change scores [22]. The MDC95 that reflected a
real change in PVF measurement has been established in
a recent study [22]. The MDC95 was found at 2% BW,
indicating that any change in PVF for OA dog would be
considered as measure noise below 2% BW, and a clinic-
ally significant change over 2% BW. However, when
expressed relatively to baseline values, the MDC95 was
found to be 3.6% BW [22]. As given that the change in
PVF was measured between T0 (baseline) and T3, we
choose this limit (3.6%) to calculate responder’s rates in
our study.
Chronic pain is complex to measure. Even if the force
plate is considered as one of the most appropriate measure
of outcome as it is the most objective, so far, it is unknown
if it is the most sensitive (pertinent) for chronic OA.
To our knowledge, this is the first time that serum OA
biomarkers were measured to assess the effects of a diet
supplemented with CCOT mixture in OA dogs. Colla-
gen degradation is one of the main features of cartilage
breakdown during OA. Coll2–1 and Coll2–1 NO2 serum
concentrations were correlated with the macroscopic
and histological changes in dogs with OA induced by
transection of the anterior cruciate ligament [34]. We
failed to observe an effect of CCOT on Coll2–1 and
Coll2–1 NO2 serum levels. This may be explained by the
higher heterogeneity of biomarker values in our popula-
tion than in a model of surgically induced OA dogs.
No age effect was observed (data not shown) on the
outcomes of interest but the study was not designed for
this purpose.
Our study presented some limitations such as its short
duration and the number of dogs included. Even though
the number of dogs needed was statistically calculated a
priori based on the PVF data, the lack of information to
fully represent targeted population variability (i.e. breed
effect, gender effect…) might have underestimated re-
quired sample size. Additionally, higher numbers are re-
quired for subjective veterinary and owner assessments
compared to gait analysis. A larger number of dogs and
a reduced inter-individual variability could increase the
benefit of the CCOT diet and subsequently reinforce the
likelihood of measurable improvements of PVF and OA
biomarkers serum concentrations. Moreover, the fact
that the bags were clearly marked with codes that differ-
entiated the groups and that the randomization se-
quence was not concealed could add bias to the study.
Conclusions
Objective variables measured, such as ground reaction
forces and OA biomarkers, did not show statistical dif-
ferences. Regarding the objective outcome PVF, the posi-
tive responder’s rate was greater in CCOT group than in
control group whereas the negative responder’s rate was
greater in control group than in CCOT group, albeit not
statistically tested. The study reveals that dogs receiving
diet supplemented with CCOT mixture for 3 months
showed less pain at manipulation. The three other pa-
rameters evaluated by veterinary subjective assessment
(lameness, pain at palpation and joint mobility) did not
show statistical differences. Regarding the subjective
owner assessment, the evolution of PS showed signifi-
cant difference between CCOT and control groups. No
statistical difference was found for PI, except for the
ability to rise to standing from lying down, which was
significantly improved in the CCOT compared to the
control group. These results suggest that, even if the
CCOT diet does not seem to improve lameness (on kin-
etics and clinical rating) in our studied OA dogs, it could
present some benefits on chronic pain and its impact on
activities of daily living in OA dogs.
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